Literature DB >> 21971700

Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.

Yi Guo1, Pingfu Fu, Honglan Zhu, Eddie Reed, Scot C Remick, William Petros, Michael D Mueller, Jing Jie Yu.   

Abstract

The aim of this study was to better understand the mechanisms of tumor development and disease progression in human epithelial ovarian cancer. Fifty genes were screened for gene signature; 20 expressed genes were assessed in tumor and normal samples of EOC patients by RT-PCR. Expression of UBE2I, EGF, TAL2 and ILF3 was validated by qPCR on the ABI Prism 7000 Detection System. ERCC1 and XPB expression was previously determined by RT-PCR in these specimens. Statistical analyses include two-sided Kruskal-Wallis test, pairwise comparison, Pearson correlation coefficient and paired t-test. In comparison to normal samples, 6 genes demonstrated distinct expression patterns in tumor tissues, with high expression observed for ERCC1, XPB and ILF3 (p=0.001, 0.0007 and 0.002, respectively) and low expression observed for TAL2 and EGF (both p<0.0001). This differential expression pattern between normal and tumor tissues may reflect in part the development of ovarian cancer. Significant differences in expression patterns of these genes in clear cell, endometrioid, mucinous and serous ovarian cancer were observed. Comparison of expression of any two EOC subtypes revealed multiple gene involvement in histopathological differentiation and cancer progression. A positive association was found between ERCC1 and XPB expression (r=0.53, p<0.0001) and between TAL2 and EGF expression (r=0.817, p<0.0001) suggesting the existence of gene linkage in these tumors. The differences in expression patterns of studied genes between tumors and normal specimens, between histological subtypes and correlations among studied genes, may indicate their involvement in tumor growth and disease progression in human epithelial ovarian cancer. Further investigation of these genes may enable better understanding of the molecular mechanism of tumorigenesis and identification of potential biomarkers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21971700     DOI: 10.3892/or.2011.1483

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  25 in total

1.  Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors.

Authors:  Hend Kothayer; Sebastian M Spencer; Kaushlendra Tripathi; Andrew D Westwell; Komaraiah Palle
Journal:  Bioorg Med Chem Lett       Date:  2016-03-02       Impact factor: 2.823

2.  Upregulated expression of ILF2 in non-small cell lung cancer is associated with tumor cell proliferation and poor prognosis.

Authors:  Tingting Ni; Guoxin Mao; Qun Xue; Yifei Liu; Buyou Chen; Xuefan Cui; Liting Lv; Liangliang Jia; Yuchan Wang; Lili Ji
Journal:  J Mol Histol       Date:  2015-06-10       Impact factor: 2.611

3.  LncRNA LINC00649 promotes the growth and metastasis of triple-negative breast cancer by maintaining the stability of HIF-1α through the NF90/NF45 complex.

Authors:  Jianhua Zhang; Chuang Du; Linfeng Zhang; Yan Wang; Yingying Zhang; Jingruo Li
Journal:  Cell Cycle       Date:  2022-02-21       Impact factor: 5.173

4.  Overexpression of NF90-NF45 Represses Myogenic MicroRNA Biogenesis, Resulting in Development of Skeletal Muscle Atrophy and Centronuclear Muscle Fibers.

Authors:  Hiroshi Todaka; Takuma Higuchi; Ken-ichi Yagyu; Yasunori Sugiyama; Fumika Yamaguchi; Keiko Morisawa; Masafumi Ono; Atsuki Fukushima; Masayuki Tsuda; Taketoshi Taniguchi; Shuji Sakamoto
Journal:  Mol Cell Biol       Date:  2015-04-27       Impact factor: 4.272

5.  Novel interactions between the HTLV antisense proteins HBZ and APH-2 and the NFAR protein family: Implications for the HTLV lifecycles.

Authors:  Jane Murphy; William W Hall; Lee Ratner; Noreen Sheehy
Journal:  Virology       Date:  2016-04-22       Impact factor: 3.616

6.  Suppression of MicroRNA-7 (miR-7) Biogenesis by Nuclear Factor 90-Nuclear Factor 45 Complex (NF90-NF45) Controls Cell Proliferation in Hepatocellular Carcinoma.

Authors:  Takuma Higuchi; Hiroshi Todaka; Yasunori Sugiyama; Masafumi Ono; Nobuyuki Tamaki; Etsuro Hatano; Yuka Takezaki; Kazuhiro Hanazaki; Takeshi Miwa; Sylvia Lai; Keiko Morisawa; Masayuki Tsuda; Taketoshi Taniguchi; Shuji Sakamoto
Journal:  J Biol Chem       Date:  2016-08-12       Impact factor: 5.157

7.  Identification of gene signatures and potential therapeutic targets for acquired chemotherapy resistance in gastric cancer patients.

Authors:  Jie Sun; Jingjing Zhao; Zhenkun Yang; Zhiyi Zhou; Peihua Lu
Journal:  J Gastrointest Oncol       Date:  2021-04

8.  Development and Validation of a RNA Binding Protein-Associated Prognostic Model for Hepatocellular Carcinoma.

Authors:  Ming Wang; Feng Jiang; Ke Wei; Jimei Wang; Guoping Zhou; Chuyan Wu; Guoyong Yin
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

9.  Long non-coding RNA SNHG1 suppresses cell migration and invasion and upregulates SOCS2 in human gastric carcinoma.

Authors:  Shanshan Wang; Haibo Han; Junling Meng; Wei Yang; Yunwei Lv; Xianzi Wen
Journal:  Biochem Biophys Rep       Date:  2021-06-17

10.  Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.

Authors:  Yong Han; Hao Huang; Zhen Xiao; Wei Zhang; Yanfei Cao; Like Qu; Chengchao Shou
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.